The Effect of Nonsurgical Periodontal Therapy on HNP1-3 Level in Gingival Crevicular Fluid of Chronic Periodontitis Patients

Arch Immunol Ther Exp (Warsz). 2017 Aug;65(4):355-361. doi: 10.1007/s00005-016-0451-5. Epub 2017 Feb 15.

Abstract

The rich bacterial flora of oral cavity is controlled by innate immune response, including antibacterial peptides and among them human neutrophil peptides 1-3 (HNP1-3). The knowledge of the involvement of HNPs in innate and acquired immunity of the periodontium is fragmentary. The aim of the study was to assess alterations in HNP1-3 levels in the gingival crevicular fluid (GCF) of chronic periodontitis patients before and after nonsurgical periodontal therapy. Nineteen patients with chronic periodontitis were qualified to the study. After periodontal examination, one site with pocket depth (PD) ≥4 mm was selected. All the patients received periodontal treatment involving scaling and root planing with additional systemic antibiotic therapy (Amoxicillin 375 mg three times daily and Metronidazole 250 mg three times daily for 7 days). Prior to therapy, 3 and 6 months after it, clinical periodontal parameters were measured and GCF was collected from previously chosen site. The level of HNP1-3 in GCF was determined by means of a commercially available enzyme-linked immunoassay kit. The periodontal therapy caused a statistically significant (p < 0.001) decrease in all the assessed clinical parameters at the sites of sample collection except for bleeding on probing. The level of HNP1-3 per measure point showed a statistically significant increase (baseline-3 months: p = 0.05, baseline-6 months: p = 0.007). Within the limits of the study, it can be stated that nonsurgical periodontal therapy with additional systemic administration of Amoxicillin and Metronidazole increases the level of HNP1-3 in GCF.

Keywords: Alpha-defensins; Chronic periodontitis; Gingival crevicular fluid; Human neutrophil peptide.

MeSH terms

  • Amoxicillin / therapeutic use
  • Anti-Infective Agents / metabolism*
  • Chronic Periodontitis / immunology*
  • Chronic Periodontitis / therapy
  • Defensins / metabolism*
  • Dental Scaling
  • Gingival Crevicular Fluid / metabolism*
  • Humans
  • Immunity, Innate
  • Metronidazole / therapeutic use
  • Middle Aged
  • Mouth / immunology*
  • Mouth / microbiology
  • Treatment Outcome
  • Up-Regulation
  • alpha-Defensins / metabolism*

Substances

  • Anti-Infective Agents
  • Defensins
  • alpha-Defensins
  • human neutrophil peptide 1
  • human neutrophil peptide 3
  • neutrophil defensin hNP2, human
  • Metronidazole
  • Amoxicillin